IMRX · Immuneering Corp

Track IMRX — free

$5.25 -0.08 (-1.50%) At close · Aug 20

Market Cap

$344.84M

64.70M

Up next

Next earnings call

Dec 19, 2026 Est · unconfirmed · in 17 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 5, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg −2%

below

Price vs 50-day avg +12%

above

RSI (14) 62

neutral

MACD trend Positive

52-week position 31%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return +20%

trailing

6-month return +5%

trailing

YTD return −20%

this year

Relative strength −6%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+18% holders QoQ · +37 funds added

Insider flow Accumulating

Net +$36.0K over 90 days · 0% sells

Short interest Rising

23.81% of float · ▲ +1.3% MoM · 20.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

112 holders — near 3-yr high, broad support

Squeeze score 89

high risk · 0–100

Fundamentals

Fair

Revenue growth −100%

Y/Y

EPS growth +38%

Y/Y

Free cash flow $-45.5M

Balance sheet $128.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 100%

annualized · 1-yr

Max drawdown −58%

past year

ATR 4.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 5 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−2% Neutral

Price vs 50-day avg

+12% Bullish

RSI (14)

62 Neutral

MACD trend

Positive Bullish

52-week position

31% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+18% holders QoQ · +37 funds added

Insider flow Accumulating

Net +$36.0K over 90 days · 0% sells

Short interest Rising

23.81% of float · ▲ +1.3% MoM · 20.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

112 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $5 · 31% Range high $9

vs 200-day avg -2% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and marketable securities	$182.7M	as of June 30, 2026	—
Patients weight stable or gained weight at 3 months	84%	Phase 2a data presented at ASCO 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IMRX Immuneering Corp this stock	$344.84M	-20.2%	-100.0%	—	23.8%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

112

% held: 54.4%
Net QoQ: +5.5M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

15.4M

Days to cover: 20.4d
Change: +192.9K sh

View

Short Volume

Short vol %

66%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

5.5K

Value: $23.3K
As of: Jul 29, 2026

View

Off-Exchange

Off-exchange %

36.4%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$36.0K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-56.0M
EPS diluted: $-1.27

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 11

View

Proposed Sales

Value

$136.1K

Shares: 14.0K
Filed: Sep 23, 2025

View

Exempt Offerings

Offering

$25.0M

Filed: Sep 9, 2025

View

Earnings & Events

Earnings Calls

Last call

Jun 1, 2026

View

Performance

	5D	20D	120D	MTD	YTD
IMRX	+1.0%	+19.6%	+5.2%	+27.1%	-20.2%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+2.9%	+16.3%	-6.0%	+25.0%	-32.0%

Key facts CIK 1790340 CUSIP 45254E107 13F (30d) 108 filings 107 filers Visit website Investor relations

IMRX · Immuneering Corp

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance